ACS Chemical Neuroscience

Letter

Subscriber access provided by SIMON FRASER UNIV BURNABY

A Novel Radiotracer for Imaging Monoacylglycerol Lipase in the Brain Using Positron Emission Tomography

Changning Wang, Michael S. Placzek, Genevieve C. Van de Bittner, Frederick A Schroeder, and Jacob M. Hooker

ACS Chem. Neurosci., Just Accepted Manuscript • DOI: 10.1021/acschemneuro.5b00293 • Publication Date (Web): 22 Dec 2015 Downloaded from http://pubs.acs.org on December 26, 2015

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



ACS Chemical Neuroscience is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

 A Novel Radiotracer for Imaging Monoacylglycerol Lipase in the Brain Using Positron Emission Tomography

Changning Wang^{1,*}, Michael S. Placzek^{1, 2}, Genevieve C. Van de Bittner¹, Frederick A. Schroeder¹, Jacob M. Hooker¹

¹Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, United States ² Department of Psychiatry, McLean Imaging Center, McLean Hospital, Harvard Medical School, Belmont, Massachusetts 02478, United States

ABSTRACT

Monoacylglycerol lipase (MAGL) is a serine hydrolase that hydrolyzes monoacylglycerols to glycerol and fatty acid and plays an important role in neuroinflammation. MAGL inhibitors are a class of molecules with therapeutic potential for human diseases of the central nervous system (CNS), in areas such as pain and inflammation, immunological disorders, neurological and psychiatric conditions. Development of a non-invasive imaging probe would elucidate the distribution and functional roles of MAGL in the brain and accelerate medical research and drug discovery in this domain. Herein, we describe the synthesis and pilot rodent imaging of a novel MAGL imaging agent, [¹¹C]SAR127303. Our imaging results demonstrate the high specificity, good selectivity, and appropriate kinetics and distribution of [¹¹C]SAR127303, validating its utility for imaging MAGL in the brain. Our findings support the translational potential for human CNS MAGL imaging.

KEYWORDS: Monoacylglycerol lipase, PET, radiotracer, brain, CNS

INTRODUCTION

Monoacylglycerol lipase (MAGL) is a serine hydrolase that hydrolyzes monoacylglycerols to glycerol and fatty acid, with highest expression in brain, white adipose tissue, and liver. ¹⁻³ MAGL primarily degrades the endogenous cannabinoid, 2-arachidonoyglycerol (2-AG), one of the two main transmitters of the endogenous cannabinoid system. ^{1, 4, 5} Low levels of 2-AG have been observed in pain and inflammation ^{6, 7}, immunological disorders ⁸, neurological and psychiatric conditions ⁹, obesity and metabolic syndromes ^{10, 11} and cancer. ¹²

In neuroinflammatory regions, MAGL is upregulated to produce less 2-AG. ¹³⁻¹⁵ Both genetic and pharmacological blockades of MAGL show anti-inflammatory effects in the brain and neuroprotective effects in mouse models of Parkinson's disease and Alzheimer's disease, two examples of profound brain dysfunction involving neuroinflammation. ^{14, 15} In addition, a recent study found that MAGL releases arachidonic acid (AA), the precursor for pro-inflammatory prostaglandin synthesis in certain tissues. Inhibiting MAGL lowered AA levels in the brain (elevation of 2-AG), which resulted in reduced levels of pro-inflammatory prostaglandin and thromboxane.¹⁴ The importance of MAGL in neuroinflammatory diseases has led to the development of MAGL-selective inhibitors ^{1, 16, 17}, such as JZL184 and KML29, which are in the *O*-aryl carbamate class ^{13, 18}. MAGL blockade by JZL184 reduced colonic pro-inflammatory cytokines in a trinitrobenzene sulfonic acid-induced colitis model resulting in reduced brain inflammation. ¹⁹ Currently, it is not possible to interrogate target engagement of MAGL inhibitors *in vivo*. One result of this is the slowed optimization of small molecule inhibitors for clinical application, including leads from the carbamate class.

Understanding the relationship between MAGL engagement in the brain and inhibitor dosing is essential to advancing the MAGL therapeutic discovery and dose selection process. Molecular imaging, such as positron emission tomography (PET), is an ideal tool to study the drug-target interaction as it is non-invasive, has exquisite sensitivity and selectivity, and can be translated to human brain imaging. Developing novel MAGL PET imaging probes will significantly accelerate the entire process of investigating MAGL expression and activity in the brain, quickly identifying lead MAGL inhibitors in preclinical and translational research.

ACS Chemical Neuroscience

However, to our knowledge, no PET radiotracers targeting MAGL have been reported. Although efforts have been made to evaluate several radiolabeled MAGL inhibitors, these compounds lack sufficient brain uptake required for PET brain imaging.²⁰ Herein, we report a novel MAGL PET radiotracer ([¹¹C]SAR127303), which is based on a highly potent and selective MAGL inhibitor (SAR127303) ⁴ and demonstrates suitable pharmacokinetic properties in a pilot rodent study.

RESULTS AND DISCUSSION

Physiochemical properties of SAR127303

A number of major factors determine the success of a radiotracer candidate for imaging MAGL in the brain. The binding affinity and selectivity for MAGL must be high enough to produce sufficient signal for detection. SAR127303 has been recently developed and evaluated by Sanofi.⁴ SAR127303 is a highly selective inhibitor of mouse and human MAGL (IC₅₀ = 3.8 and 29 nM, respectively).⁴ The binding selectivity of SAR127303 was tested on more than 200 targets (receptors, ion channels, enzymes, transporters and kinases), including cannabinoid receptors (CB1 and CB2) and other human serine hydrolases (e.g. FAAH) at 10 mM. No significant inhibition was observed against these targets, with the exception of α/β -hydrolase 6 (ABHD6, a serine hydrolase for 2-AG hydrolysis).⁴ However, MAGL is responsible for approximately 85% of CNS-centered 2-AG hydrolysis ^{21, 22} while ABHD6 only accounts for approximately 4% of brain 2-AG hydrolase activity ^{22, 23}, indicating radiolabeled SAR127303 could be used as a probe for monitoring MAGL-regulated 2-AG hydrolysis.

High brain uptake of the radiotracer is important for imaging MAGL in the brain. The molecular weight, measured log *D* and total polar surface area (tPSA) of SAR127303 are within the typical range for small molecules that demonstrate good brain penetration (**Figure 1**). Indeed, the brain to plasma ratio of SAR127303 is above 10 after p.o. administration to male mice at 10 mg/kg. ⁴ Therefore, SAR127303 is an ideal good probe candidate for radiolabeling and subsequent brain imaging of MAGL with PET.

Synthesis of SAR127303 and the PET imaging agent, [¹¹C]SAR127303

To date, most MAGL inhibitors, including SAR127303, are carbamate-based inhibitors that form irreversible, covalent bonds between the carbamoyl moiety and Ser132 of the enzyme's catalytic

triad with the expulsion of a leaving group.²⁴ Therefore, the carbamoyl group is an ideal radiolabeling site. The chemical synthesis of SAR127303 (**Scheme 1**) and its intermediates were performed by SAI Life Sciences Ltd. Briefly, intermediate **3** was prepared by the coupling reaction with **1** and **2**. Compound **3** was allowed to react with the intermediate formed from **4** and **5** to afford the desired product SAR127303.

To insert the radiolabel at the carbonyl of the carbamate, a one-pot [11 C]CO₂ fixation method was employed (**Scheme 2**)²⁵, which is a base-catalyzed reaction that forms carbamates from [11 C]CO₂. Briefly described, [11 C]SAR127303 was synthesized by bubbling cyclotron-produced [11 C]CO₂ into a sealed vial with **3** in acetonitrile in the presence of 2-tert-butylimino-2- diethylamino-1,3dimethylperhydro-1,3,2-diazaphosphorine (BEMP). ²⁰ When activity peaked, POCl₃ was added and the mixture was stirred for 1 minute to form the putative mixed anhydride. Hexafluoroisopropanol (HFIP) was then introduced and the mixture was stirred for 1 minute before quenching with water. All radiochemistry was carried out with no heating or cooling, as previously described, ²⁰ and purified by semi-preparative HPLC. Radiosynthesis of [11 C]SAR127303 was prepared 30–34 min after end of bombardment (EOB) with adequate radiochemical yields (3–6%, non-decay corrected, calculated from initial trapped [11 C]CO₂) and final formulation ready for injection with high radiochemical purity (>95%) and good specific activity (1.6-2.3 mCi/nmol at time of injection).

In vivo PET-CT imaging with [¹¹C]SAR127303 in rodents

Initial evaluation of [¹¹C]SAR127303 *in vivo* was conducted in rodents with dynamic brain PET. [¹¹C]SAR127303 exhibited high BBB penetration and sustained binding over the 60 min scan when administered by intravenous bolus injection (0.2-0.5 mCi (80-310 ng) per animal), as shown in **Figure 2**. [¹¹C]SAR127303 displayed highest uptake in the cortex, thalamus and cerebellum. Based on a whole-brain analysis, the concentration of [¹¹C]SAR127303 in the brain reached a maximum at \sim 2 min post-injection.

To investigate the specificity of [¹¹C]SAR127303, we performed PET imaging studies in rats with 5 min i.v. pretreatment of unlabeled SAR127303 at 0.05, 0.1, 1.0 and 2.0 mg/kg. At 0.05 mg/kg, we found a 48 % reduction in binding, estimated as the percent change in whole-brain radioactivity

ACS Chemical Neuroscience

between peak uptake at 2 min and the lowest uptake at 60 min (**Figure 2**). Increasing the dose of unlabeled SAR127303 to 0.1 mg/kg resulted in a ~67% reduction in [11C]SAR127303 brain uptake, and we observed a similar blockade with 1.0 and 2.0 mg/kg unlabeled SAR127303, indicating saturation at 0.1 mg. This finding demonstrates a high saturability of [11 C]SAR127303 for MAGL, with a dose-dependent response to self-blockade and ~30% of uptake attributed to non-specific binding.

To support the notion that [¹¹C]SAR127303 was not effluxed from the brain by the P-glycoprotein (P-gp), we measured radioligand uptake in brain after treatment with the P-gp inhibitor, cyclosporin A (CsA) and found no difference compared to control treatment (**Figure 3A**). Additionally, [¹¹C]SAR127303 binding in rat brain was not disrupted ($k_{off} = 0$) by i.v. challenge with unlabeled SAR127303 20 min after tracer administration.²⁶ This provided confirmation of the irreversibility of [¹¹C]SAR127303 binding to MAGL (**Figure 3B**).

To test the ability of [¹¹C]SAR127303 as a tool for evaluation of MAGL inhibitors in the brain, we performed a study with 5 min pretreatment of two MAGL selective inhibitors, JZL184 and JW 642. From our imaging results, JW642 showed good blockade in the brain, however, JZL184 did not, suggesting that JW642 has good brain permeability and MAGL inhibition, while JZL184 has limited brain uptake or poor MAGL engagement at this dose (**Figure 4**).

Our data in rodents support [¹¹C]SAR127303 as a new tool to visualize MAGL density in the living brain. The robust brain uptake of [¹¹C]SAR127303 potentially offers a method for quantification of MAGL density in inflammation-associated brain disorders, such as neurodegenerative diseases and mood disorders. We also anticipate utility of [¹¹C]SAR127303 for *in vivo* evaluation of target engagement of novel therapeutics early in compound development pipeline.

CONCLUSION

In summary, [¹¹C]SAR127303 binds to MAGL with high selectivity and specificity and provides a potential tool for quantitative imaging of MAGL density in the brain of living subjects. We are progressing [¹¹C]SAR127303 forward for evaluation as a novel MAGL PET radiotracer in non-human primates and humans.

METHODS

General methods and materials

Compound 3 and SAR127303 were prepared form SAI Life Sciences Ltd, Telangana, India. JZL184 and JW642 were purchased from Tocris Bioscience. Minneapolis, MN. All other reagents and solvents were of ACS-grade purity or higher and used without further purification. NMR data were recorded on a Varian 400 MHz magnet and were reported in ppm units downfield from trimethylsilane. Analytical separation was conducted on an Agilent 1100 series HPLC fit with a diode-array detector, quaternary pump, vacuum degasser, and autosampler. Mass spectrometry data were recorded on an Agilent 6310 ion trap mass spectrometer (ESI source) connected to an Agilent 1200 series HPLC equipped with a quaternary pump, vacuum degasser, diode-array detector, and an autosampler. [¹¹C]CO₂ (1.2 Ci) was obtained via the ¹⁴N (p, α) ¹¹C reaction with nitrogen in the presence of 2.5% oxygen, with 11 MeV protons (Siemens Eclipse cyclotron), and trapped on molecular sieves in a TRACERlab FX-MeI synthesizer (General Electric).

All animal studies were carried out at Massachusetts General Hospital (PHS Assurance of Compliance No. A3596-01). The Subcommittee on Research Animal Care (SRAC) serves as the Institutional Animal Care and Use Committee (IACUC) for the Massachusetts General Hospital (MGH). SRAC reviewed and approved all procedures detailed in this paper.

PET/CT imaging was performed in anesthetized (isoflurane) Sprague-Dawley rats. Highly-trained animal technicians monitored animal safety throughout all procedures and veterinary staff were responsible for daily care. All animals were socially housed in cages appropriate for the physical and behavioral health of the animals. Animals were given unlimited access to food and water.

Chemical synthesis

4-chloro-N-(piperidin-4-ylmethyl)benzenesulfonamide (3)

4-chlorobenzenesulfonyl chloride (1) (0.84 g, 4 mmol) and tert-butyl 4-(aminomethyl)piperidine-1-carboxylate (2) (0.85 g, 4 mmol) were added to a chilled solution (0 °C, ice water bath) in the presence of diisopropylethyl amine (DIPEA) (0.78 g, 6 mmol) and 4-dimethylaminopyridine (DMAP) (0.049 g, 0.4 mmol) in dichloromethane (DCM) (15 mL). After 16 h, the solvent was

removed under vacuum and the residue partitioned between DCM and water (20 mL each). The organic layer was washed with brine (20 mL), dried with Na₂SO₄, filtered, and the solvent was removed under vacuum. Crude products were purified by flash chromatography. Pure fractions were combined, the solvent removed and solids were collected (1.12 g, yield 72%). ¹H-NMR (400 MHz, CDCl₃): δ 7.80 (d, *J* = 8.4 Hz, 2H), 7.51 (d, *J* = 8.4 Hz, 2H), 4.59-4.62 (m, 1H), 4.11 (s, 2H), 2.83-2.86 (m, 2H), 2.62-2.65 (m, 2H), 1.58-1.67 (m, 2H), 1.45 (s, 9H), 1.02-1.27 (m, 2H). The product from the previous step (1.1 g, 2.8 mmol) was dissolved in DCM chilled over an ice water bath (0 °C). TFA (3.2 g, 28 mmol) was added and stirred for 16 h. The solvent was removed under vacuum and the residue partitioned between DCM and sodium bicarbonate solution (20 mL each). The organic layer was washed with brine (20 mL), dried (Na₂SO₄), filtered, and the solvent was removed under vacuum. Crude products were purified by flash chromatography. Pure fractions were combined, the solvent removed and the product (**3**) was collected (0.7 g, yield 85%). ¹H-NMR (400 MHz, CDCl₃): δ 7.80 (d, *J* = 8.4 Hz, 2H), 7.50 (d, *J* = 8.4 Hz, 2H), 4.62 (s, 1H), 3.05 (d, *J* = 12 Hz, 2H), 2.83 (d, *J* = 9.6 Hz, 2H), 2.51-2.57 (m, 2H), 1.57-1.66 (m, 2H), 1.02-1.10 (m, 2H). LC-MS calculated for C₁₂H₁₇ClN₂O₂S [M]: 288.1; found [M+H]⁺: 289.1.

1,1,1,3,3,3-hexafluoropropan-2-yl4-(((4-chlorophenyl)sulfonamido)methyl)piperidine-1-carboxylate (SAR127303)

HFIP (4) (0.17 g, 1 mmol) was added to a chilled solution (0 °C, ice water bath) of 4-nitrophenyl carbonochloridate (5) (0.4 g, 2 mmol), pyridine (0.16 g, 2 mmol) and DMAP (0.006 g, 0.05 mmol) in DCM (3 mL). After 16 h, a solution of **3** (0.3g, 1 mmol) and DIPEA (0.33 g, 2.5 mmol) in DCM (15 mL) was added dropwise and after 30 min the solvent was removed under vacuum and the residue partitioned between DCM and water (20 mL each). The organic layer was washed with brine (20 mL), dried (Na₂SO₄), filtered, and the solvent was removed under vacuum. Crude products were purified by flash chromatography. Pure fractions were combined, the solvent removed and solids were precipitated from pentane. The final product (SAR127303) was collected (0.06 g, yield 8%). Purity of SAR127303 was >99% as measured by HPLC. ¹H-NMR (400 MHz, CDCl₃): δ 7.80 (d, *J* = 8.0 Hz, 2H), 7.52 (d, *J* = 8.4 Hz, 2H), 5.71-5.76 (m, 1H), 4.51-4.55 (m, 1H), 4.14-4.21 (m, 2H), 2.81-2.93 (m, 4H), 1.71-1.80 (m, 2H), 1.12-1.18 (m, 2H). LC-MS calculated for C₁₆H₁₇ClF₆N₂O₄S [M]: 482.0; found [M-H]⁺: 480.7.

Radiosynthesis of [¹¹C]SAR127303

A conical vial (1 mL) sealed with a Teflon-lined silicone septum was purged with N₂ (15 mL/min for 5 min) 10 min prior to the end-of-bombardment and then charged with a solution of **3** (1 mg) and BEMP (7 μ L) in anhydrous CH₃CN (100 μ L). Carbon-11 labeled CO₂ was dispensed in a stream of nitrogen (15 mL/min) into the conical vial until radioactivity peaked. One min later, a solution of POCl₃ (0.3 μ L) in CH₃CN (100 μ L) was added followed 1 min later by a CH₃CN solution (100 μ L) of HFIP (1.5 μ L). After 1 min, the reaction was quenched with water (700 μ L) and purified on a reverse phase semi-preparative HPLC (Agilent Eclipse XDB-18 column, 5 μ m, 9.4×250 mm, 5.0 mL/min, 35% H₂O + 0.1% TFA / 65% CH₃CN + 0.1% TFA, 254 nm) and the desired fraction was collected. The final product was diluted with 20 mL water and reformulated by loading onto a solid-phase exchange (SPE) C-18 cartridge, rinsing with water (5 mL), eluting with EtOH (1 mL), and diluting with saline (9 mL). The chemical and radiochemical purity of the final product was tested by analytical HPLC (Agilent Eclipse XDB-C18, 150 mm x 4.6 mm). The identity of the product was confirmed by analytical HPLC via co-injection with a SAR127303 reference standard. Specific activity of [¹¹C]SAR127303 (at time of injection): 1.6-2.3 mCi/nmol.

Log D Determination

An aliquot (~50 µL) of the formulated radiotracer was added to a test tube containing 2.5 mL of octanol and 2.5 mL of phosphate buffer solution (pH 7.4). The test tube was mixed by vortex for 2 min and then centrifuged for 2 min to fully separate the aqueous and organic phase. A sample taken from the octanol layer (0.1 mL) and the aqueous layer (1.0 mL) was saved for radioactivity measurement. An additional aliquot of the octanol layer (2.0 mL) was carefully transferred to a new test tube containing 0.5 mL of octanol and 2.5 mL of phosphate buffer solution (pH 7.4). The previous procedure (vortex mixing, centrifugation, sampling, and transfer to the next test tube) was repeated until six sets of aliquot samples had been prepared. The radioactivity of each sample was measured in a well counter (Perkin-Elmer, Waltham, MA). The log D of each set of samples was derived by the following equation: log D = log (decay-corrected radioactivity in octanol sample x 10/decay-corrected radioactivity in phosphate buffer sample).

Rodent PET/CT Acquisition and Post Processing

Male Sprague-Dawley rats were utilized in pairs, anesthetized with inhalational isoflurane at 3% in a carrier of 1.5 L/min medical oxygen and maintained at 2% isoflurane for the duration of the scan. The rats were arranged side-by-side in a Triumph Trimodality PET/CT/SPECT scanner (Gamma Medica, Northridge, CA). Rats were injected with unlabeled SAR127303 or vehicle via a lateral tail vein catheterized at the start of PET acquisition. Dynamic PET acquisition lasted for 60 min and was followed by computed tomography (CT) for anatomic co-registration and PET attenuation correction. PET data were reconstructed using a 3D-MLEM method resulting in a full width at half-maximum resolution of 1 mm. Reconstructed images were exported from the scanner in DICOM format along with an anatomic CT for rodent studies. These files were imported to PMOD (PMOD Technologies, Ltd.) and manually co-registered using six degrees of freedom.

Rodent PET/CT Image Analysis

Volumes of interest (VOIs) were drawn manually as spheres in brain regions guided by high resolution CT structural images and summed PET data, with a radius no less than 1mm to minimize partial volume effects. Time-activity curves (TACs) were exported as decay-corrected activity per unit volume. The TACs were expressed as percent injected dose per unit volume for analysis.

AUTHOR INFORMATION

Corresponding Author:

*Mailing address: Athinoula A. Martinos Center for Biomedical Imaging Massachusetts General Hospital, CNY 149, Room 5.022A 149 13th Street, Charlestown, MA 02179. Phone: 617.724.9390. E-mail: cwang15@mgh.harvard.edu.

Author Contributions:

C.W. discovered, synthesized and purified [¹¹C]SAR127303. C.W. and J.M.H. planned experiments, performed data analysis. C.W., M.S.P., G.V..d.B. and F.A.S. performed the experiments. The manuscript was written through contributions of all the authors. All authors have given approval to the final version of the manuscript.

Funding:

This research was supported by the Harvard/MGH Nuclear Medicine Training Program from the Department of Energy under Grant DE-SC0008430 (C.W.) and NIH-NIDA T32 postdoctoral fellowship T32DA015036 (M.S.P.). This research was carried out at the Athinoula A. Martinos Center for Biomedical Imaging at the Massachusetts General Hospital, using resources provided by the Center for Functional Neuroimaging Technologies, P41EB015896, a P41 Regional Resource supported by the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health. This work also involved the use of instrumentation supported by the NIH Shared Instrumentation Grant Program and/or High-End Instrumentation Grant Program; specifically, grant numbers: S10RR015728.

Notes:

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

The authors are grateful to the Martinos Center radiopharmacy staff (Judit Sore, Kari Phan, Garima Gautam and Samantha To) for help with radiotracer production. The authors are grateful to Dr. Aijun Zhu for assisting the rodent PET-CT studies.

ABBREVIATIONS

MAGL, monoacylglycerol lipase; PET, positron emission tomography; CT, computed tomography; EOS, end of synthesis; RCY, radiochemical yield; VOI, volume of interest; TAC, time-activity curves; BEMP, (2-tert-butylimino-2- diethylamino-1,3-dimethylperhydro-1,3,2diazaphosphorine); HFIP, hexafluoroisopropanol; tPSA, total polar surface area; FAAH, fatty acid amide hydrolase; ABHD6, α/β -hydrolase 6; TFA, Trifluoroacetic acid; SPECT, single-photon emission computed tomography; SPE, solid-phase exchange; DIPEA, diisopropylethyl amine; DCM, dichloromethane; DMAP, 4-Dimethylaminopyridine; LPS, lipopoly-saccharide; AA, arachidonic acid; AEA, N-arachidonoylethanolamine; CNS, central nervous system; PNS, peripheral nervous system; EOB, end of bombardment.

REFERENCES

1. Mulvihill, M. M.; Nomura, D. K., Therapeutic potential of monoacylglycerol lipase inhibitors. *Life Sci* 2013, 92, (8-9), 492-7.

2. Ahn, K.; McKinney, M. K.; Cravatt, B. F., Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. *Chem Rev* 2008, 108, (5), 1687-707.

3. Long, J. Z.; Cravatt, B. F., The metabolic serine hydrolases and their functions in mammalian physiology and disease. *Chem Rev* 2011, 111, (10), 6022-63.

4. Griebel, G.; Pichat, P.; Beeske, S.; Leroy, T.; Redon, N.; Jacquet, A.; Francon, D.; Bert, L.; Even, L.; Lopez-Grancha, M.; Tolstykh, T.; Sun, F.; Yu, Q.; Brittain, S.; Arlt, H.; He, T.; Zhang, B.; Wiederschain, D.; Bertrand, T.; Houtmann, J.; Rak, A.; Vallee, F.; Michot, N.; Auge, F.; Menet, V.; Bergis, O. E.; George, P.; Avenet, P.; Mikol, V.; Didier, M.; Escoubet, J., Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents. *Sci Rep* 2015, 5, 7642.

5. Pertwee, R. G., The pharmacology of cannabinoid receptors and their ligands: an overview. *Int J Obes (Lond)* 2006, 30 Suppl 1, S13-8.

6. Hohmann, A. G.; Suplita, R. L., 2nd, Endocannabinoid mechanisms of pain modulation. *AAPS J* 2006, 8, (4), E693-708.

7. Jhaveri, M. D.; Richardson, D.; Chapman, V., Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. *Br J Pharmacol* 2007, 152, (5), 624-32.

8. Lambert, D. M., Allergic contact dermatitis and the endocannabinoid system: from mechanisms to skin care. *ChemMedChem* 2007, 2, (12), 1701-2.

9. Bisogno, T.; Di Marzo, V., Short- and long-term plasticity of the endocannabinoid system in neuropsychiatric and neurological disorders. *Pharmacol Res* 2007, 56, (5), 428-42.

10. Matias, I.; Di Marzo, V., Endocannabinoids and the control of energy balance. *Trends Endocrinol Metab* 2007, 18, (1), 27-37.

Pagotto, U.; Marsicano, G.; Cota, D.; Lutz, B.; Pasquali, R., The emerging role of the endocannabinoid system in endocrine regulation and energy balance. *Endocr Rev* 2006, 27, (1), 73-100.
Bifulco, M.; Laezza, C.; Gazzerro, P.; Pentimalli, F., Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (review). *Oncol Rep* 2007, 17, (4), 813-6.

13. Long, J. Z.; Li, W.; Booker, L.; Burston, J. J.; Kinsey, S. G.; Schlosburg, J. E.; Pavon, F. J.; Serrano, A. M.; Selley, D. E.; Parsons, L. H.; Lichtman, A. H.; Cravatt, B. F., Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. *Nat Chem Biol* 2009, 5, (1), 37-44.

14. Nomura, D. K.; Morrison, B. E.; Blankman, J. L.; Long, J. Z.; Kinsey, S. G.; Marcondes, M. C.; Ward, A. M.; Hahn, Y. K.; Lichtman, A. H.; Conti, B.; Cravatt, B. F., Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. *Science* 2011, 334, (6057), 809-13.

15. Schlosburg, J. E.; Blankman, J. L.; Long, J. Z.; Nomura, D. K.; Pan, B.; Kinsey, S. G.; Nguyen, P. T.; Ramesh, D.; Booker, L.; Burston, J. J.; Thomas, E. A.; Selley, D. E.; Sim-Selley, L. J.; Liu, Q. S.; Lichtman, A. H.; Cravatt, B. F., Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. *Nat Neurosci* 2010, 13, (9), 1113-9.

16. Fowler, C. J., Monoacylglycerol lipase - a target for drug development? *Br J Pharmacol* 2012, 166, (5), 1568-85.

17. King, A. R.; Dotsey, E. Y.; Lodola, A.; Jung, K. M.; Ghomian, A.; Qiu, Y.; Fu, J.; Mor, M.; Piomelli, D., Discovery of potent and reversible monoacylglycerol lipase inhibitors. *Chem Biol* 2009, 16, (10), 1045-52.

18. Chang, J. W.; Niphakis, M. J.; Lum, K. M.; Cognetta, A. B., 3rd; Wang, C.; Matthews, M. L.; Niessen, S.; Buczynski, M. W.; Parsons, L. H.; Cravatt, B. F., Highly selective inhibitors of monoacylglycerol lipase bearing a reactive group that is bioisosteric with endocannabinoid substrates. *Chem Biol* 2012, 19, (5), 579-88.

19. Alhouayek, M.; Lambert, D. M.; Delzenne, N. M.; Cani, P. D.; Muccioli, G. G., Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. *FASEB* J 2011, 25, (8), 2711-21.

20. Hicks, J. W.; Parkes, J.; Tong, J.; Houle, S.; Vasdev, N.; Wilson, A. A., Radiosynthesis and ex vivo evaluation of [(11)C-carbonyl]carbamate- and urea-based monoacylglycerol lipase inhibitors. *Nucl Med Biol* 2014, 41, (8), 688-94.

21. Saario, S. M.; Savinainen, J. R.; Laitinen, J. T.; Jarvinen, T.; Niemi, R., Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. *Biochem Pharmacol* 2004, 67, (7), 1381-7.

22. Savinainen, J. R.; Saario, S. M.; Laitinen, J. T., The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. *Acta Physiol (Oxf)* 2012, 204, (2), 267-76.

23. Saario, S. M.; Salo, O. M.; Nevalainen, T.; Poso, A.; Laitinen, J. T.; Jarvinen, T.; Niemi, R., Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes. *Chem Biol* 2005, 12, (6), 649-56.

24. Long, J. Z.; Nomura, D. K.; Cravatt, B. F., Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. *Chem Biol* 2009, 16, (7), 744-53.

25. Hooker, J. M.; Reibel, A. T.; Hill, S. M.; Schueller, M. J.; Fowler, J. S., One-pot, direct incorporation of [11C]CO2 into carbamates. *Angew Chem Int Ed Engl* 2009, 48, (19), 3482-5.

26. Rusjan, P. M.; Wilson, A. A.; Mizrahi, R.; Boileau, I.; Chavez, S. E.; Lobaugh, N. J.; Kish, S. J.; Houle, S.; Tong, J., Mapping human brain fatty acid amide hydrolase activity with PET. *J Cereb Blood Flow Metab* 2013, 33, (3), 407-14.

Graph abstract



ACS Paragon Plus Environment



Figure 1. SAR127303 is a highly selective inhibitor of mouse and human MAGL. Griebel et al. reported the pharmacokinetics of SAR127303 recetly.⁴ Single oral administration (P.O.) of SAR127303 at 10 mg/kg showed high concentration in mouse brain. Plasma and brain C_{max} were observed at 4 hours after SAR127303 administration.⁴



Scheme 1. Reagents and conditions: (a) 1 (1.0 eq), 2 (1.0 eq), DIPEA (1.5 eq), DMAP (0.1 eq), DCM (15 mL), 0 °C to rt, 16 h, 72%; (b)), TFA (10 eq), DCM (2 mL), 0 °C - rt, 16 h, 85%; (c) 4 (1.0 eq), 5 (2.0 eq), Pyridine (2.0 eq), DMAP (0.05 eq), DCM (3 mL), 0 °C - rt, 16 h; then 3 (1.0 eq), DIPEA (2.5 eq), DCM (15 mL), 0 °C - rt, 16 h, 8%.



Scheme 2. [¹¹C]CO₂ fixation reaction forming [¹¹C]SAR127303. a = POCl₃, 1 min, rt; b = HFIP, 1 min, rt, then quenched with water and purified by HPLC. Radiochemical yield (RCY): 3-6% based on the trapped [¹¹C]CO₂ (decay-uncorrected). Specific activity at time of injection:1.6-2.3 mCi/nmol.



Figure 2. Rodent *in vivo* PET imaging with [11 C]SAR127303 reveals blockable uptake in brain. (A) Summed PET-CT images (30-60 min) following injection with [11 C]SAR127303 at baseline or after 5-min pretreatment with 1.0 mg/kg unlabeled SAR127303 (self-blocking); (B) [11 C]SAR127303 has high uptake in the whole brain with significant blockade after pre-treatment with SAR127303 at 1.0 mg/kg; (C) [11 C]SAR127303 shows blockade in brain regions such as cortex (CTX), thalamus (THA) and cerebellum (CB) after pre-treatment with SAR127303 at 1.0 mg/kg; (D) SAR127303 pre-treatment at 0.05, 0.1, 1.0 and 2.0 mg/kg shows activity blockade in the brain.



Figure 3. (A) Brain uptake of [¹¹C]SAR127303 in rats is equivalent 30 min after pretreatment with vehicle (control) or the P-glycoprotein (Pgp) inhibitor cyclosporin A (CsA, 25 mg/kg, i.v.); (B) Equilibrium binding of [¹¹C]SAR127303 is undisrupted by administration of unlabeled SAR127303 (1.0 mg/kg, i.v.) 20 min after tracer injection, demonstrating irreversible MAGL binding in the brain.



Figure 4. (A)Structures of MAGL selective inhibitor, JZL 184 (IC₅₀ = 8 nM) and JW 642 (IC₅₀ = 3.7 nM); (B) Brain uptake of [¹¹C]SAR127303 can be blocked by JW 642 (5 min pretreatment, i.v., 1 mg/kg), demonstrating specific MAGL binding of [¹¹C]SAR127303 in the brain. The unchanged uptake of [¹¹C]SAR127303 following pretreatment with JZL 184 suggests limited brain uptake of JZL 184.